Background: We describe the differential diagnosis of an obese 12-year-old boy of Mexican origin who presented with a 6-year history of abnormal lipid profile and elevated liver transaminase levels.
NAFLD can present as liver injury ranging from steatosis to steatohepatitis, with or without fibrosis. 4 A large crosssectional study noted that the results of approximately 10% of the liver biopsies from patients with NAFLD show a variable degree of microvesicular steatosis and that the presence of NAFLD correlates with severe (ie, increased lobular inflammation) and advanced (ie, increased fibrosis) disease. 6 Small-droplet steatosis refers to the presence of several microscopically separable lipid droplets that exist within a single hepatocyte but do not fill the entire hepatocyte. 7 In contrast, true microvesicular steatosis consists of much smaller (ie, submicroscopic), uniform fat droplets dispersed throughout the hepatocyte, giving a reticulated appearance and often requiring special stains (eg, Oil Red O) or electron microscopy for detection. 6, 7 As a result, it may be easy to overlook microvesicular steatosis when admixed with large-droplet steatosis, especially given the relative frequency of NAFLD compared to other etiologies. 6 In the population we serve in Bronx County, New York, nearly 1 in 3 children in Head Start programs and 1 in 4 children in public elementary schools are obese. 8 Many of the children with obesity have abnormal serum lipid profiles and elevated aminotransferase levels, suggesting underlying DOI: 10.1093/labmed/lmy027 metabolic liver disease. 3, 9 Liver biopsy, the criterion standard for diagnosing NAFLD, 10, 11 is performed in our practice when obese children with elevated serum lipids and aminotransferases fail to improve after approximately 6 months of dietary and/or lifestyle changes. Although most of these biopsies reveal NAFLD or nonalcoholic steatohepatitis, there is a risk that rare metabolic disorders may go unrecognized due to overlapping histologic features. The surgical pathologist is therefore in a unique position to recognize subtle morphologic clues to these rare metabolic diseases, including glycogenic hepatopathy, medium-chain acyl coenzyme A dehydrogenase (MCAD), and long-chain acyl coenzyme A dehydrogenase (LCAD) deficiency, Wilson disease, Niemann-Pick disease, and lysosomal acid lipase deficiency (LAL-D).
Herein, we report the case of a 12-year-old boy of Mexican origin who was found to have diffuse microvesicular steatosis after a liver biopsy due to an abnormal lipid profile and elevated liver transaminase levels.
Case Report

Clinical History
A 12-year-old boy of Mexican origin and Hispanic ethnicity had first presented for treatment in 2010, at the age of 6 years, when he was admitted to a hospital for exacerbation of asthma. The results of a blood test performed at that time revealed elevated low-density lipoprotein cholesterol (LDL-C) and high transaminase and alkaline phosphatase (ALP) levels ( Subsequently, the patient was followed up by a pediatric gastroenterologist once every 6 months over the next few years, during which time the liver enzymes, LDL-C, and total cholesterol of the patient continued to be elevated ( Table 1) .
In August 2016, the patient was referred to the Fatty Liver Center at our hospital, The Children's Hospital at Montefiore, Bronx, NY, for additional management. His BMI at this time was 26.9 (>95 th percentile), and his liver enzyme, LDL-C, and total cholesterol remained elevated. Physical examination revealed hepatomegaly, and an abdominal ultrasound showed increased hepatic echogenicity, raising concerns for NAFLD. Given the duration and degree of liver-enzyme elevation, a decision was made to proceed with a liver biopsy at that time. Microscopic examination of the biopsy revealed diffuse, microvesicular steatosis involving more than 90% of the liver parenchyma (Images 1A and 1B); minimal (<5%) macrovesicular steatosis was also noted. Also, portal areas contained clusters of foamy histiocytes that were prominently visible on a periodic acid-Schiff diastase (PAS-D) stain (Images 1C and 1D). Occasional acidophilic bodies and scattered lobular inflammation were also observed. Pericellular and/or portal fibrosis were absent on trichrome stain (not shown), as were ballooned hepatocytes, Mallory hyaline, and satellitosis (neutrophils surrounding ballooned hepatocytes).
Differential Diagnoses
The observed morphology led to a broad differential diagnosis:
• Medication-induced hepatotoxicity: Medication-induced hepatotoxicity (Reye syndrome, tetracycline or valproic acid toxicity, etc) was ruled out because the patient was asymptomatic and had not taken any hepatotoxic medications.
• NAFLD with microvesicular steatosis: Mixed microvesicular and macrovesicular steatosis has been reported in approximately 10% of patients with NAFLD. The presence of microvesicular steatosis in NAFLD is generally associated with advanced fibrosis. 6 Liver biopsies from a number of patients with NAFLD in our practice have contained mixed large-droplet, small-droplet, and microvesicular steatosis (Images 2A and 2B); a single case of NAFLD even showed foamy histiocytes in the portal areas (Image 2B) akin to our index case (Image 1). Our patient, however, had more than 90% microvesicular steatosis, with clusters of foamy histiocytes in the lobules and portal areas.
• Glycogenic hepatopathy: First described in patients with type 1 diabetes who had hepatomegaly and elevated aminotransferase levels, glycogenic hepatopathy is clinically characterized by increased echogenicity on abdominal ultrasound, similar to that observed with fatty liver. A liver biopsy typically reveals pale and swollen hepatocytes, absent fatty change, no or minimal inflammation, and no or minimal lobular necrosis. 12 Abundant cytoplasmic glycogen deposits are typical with a periodic acid-Schiff (PAS) stain (Images 3A-3C; vs control Image 3D), and diastase digestion is able to remove the glycogen. Mechanistically, glycogenic hepatopathy results from excess accumulation of glycogen in hepatocytes after marked or prolonged hyperglycemia 
Image 2
Liver biopsy results from various patients with nonalcoholic fatty liver disease (NAFLD). A, Specimen from patient A showing mixed large-droplet, small-droplet, and microvesicular steatosis (H&E staining; original magnification ×200). B, Specimen from patient B showing mixed large-droplet, small-droplet, and microvesicular steatosis, as well as foamy histiocytes in the portal areas (H&E staining; original magnification ×200).
is treated with insulin. These changes have also been noted in patients with type 2 diabetes and in those who take steroids. 13, 14 The patient described herein did not have diabetes: his hemoglobin A 1c values were within the normal range (5.2-5.5), and a PAS stain did not reveal excess glycogen accumulation (data not shown).
• MCAD and LCAD deficiency: MCAD and LCAD deficiencies are types of fatty-acid oxidation disorders that classically present with nonhypoketotic hypoglycemia. 15 Clinically, these patients often express phenotypic variability but may have lethargy, emesis, encephalopathy, respiratory arrest, or seizures. 15 In contrast, the clinical presentation of our index patient was reasonably indolent. Liver biopsy in patients with MCAD/ LCAD deficiency often reveal prominent microvesicular steatosis, 16, 17 as observed with our patient. However, diagnosis is confirmed by measuring serum MCAD/ LCAD activity that is low and genetic testing that reveals respective mutations.
• • LAL-D: Classically, LAL-D has been described by 2 distinct phenotypes: Wolman disease and cholesterol ester storage disease (CESD). Wolman disease is characterized by little to no lysosomal acid lipase (LAL) activity (less than 1%) and usually results in death within the first year of life. 20 Infants with Wolman disease are critically ill, typically with hepatic dysfunction, failure to thrive, and significant serum cholesterol changes (high low-density lipoprotein [LDL] values). Alternately, CESD manifests in older children or adults and is believed to occur in patients with 1% to 12% LAL activity. 20 Most of these patients are believed to be asymptomatic until the development of cirrhosis, other than the characteristic biochemical profile: elevated LDL-C, low HDL-C, and elevated ALT values. Microvesicular steatosis is a hallmark of lysosomal lipid accumulation, with little difference between areas of the hepatic lobule. Individual foamy macrophages are also commonly present, with fibrosis being more common and extensive in older patients. 21 The time from initial onset of clinical/biochemical abnormalities to diagnosis is variable but can be substantial. In one study, 77% of patients were diagnosed within 5 years
Image 4
Liver biopsies from 2 patients with Niemann-Pick disease type B (H&E stain, 600X of the first reported abnormalities, but nearly 15% had to wait more than 10 years to receive the correct diagnosis.
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Follow-Up
Given his clinical presentation and constellation of histopathologic findings on biopsy, we suspected LAL-D in our patient. Serum LAL testing (Lysosomal Acid Lipase-Blood, Fluorometric Enzyme Assay, Mayo Medical Laboratories) was subsequently performed; the results demonstrated undetectable enzyme activity (0 nmol/hour/mL; reference values ≥21.0 nmol/hour/ mL). Confirmatory DNA sequencing demonstrated the presence of homozygous exon 8 splice junction mutation (E8SJM) in the LIPA gene. Testing performed in 2 of the siblings of the patient revealed that the twin sister and younger sister had absent LAL enzyme activity on dried-blood-spot testing, typical cholesterol abnormalities, and elevated ALT levels. These findings were diagnostic for LAL-D. An older brother was also tested for LAL-D but had normal enzyme-activity, LDL-C, HDL-C, and ALT levels.
Discussion
This case demonstrates the important role that surgical pathologists can play in identifying rare diseases. It also highlights the broad differential diagnoses that one must consider in patients with hepatic steatosis-specifically in those patients with microvesicular, small-droplet, or mixed steatosis.
LAL-D is a panethnic disorder caused by mutations in the LIPA gene. A review 20 of 135 patients with LAL-D revealed that the disease was most common in white people of European origin, followed by those of North American and Latin American origin. Disease prevalence is unknown but is estimated to be from 1:40,000 to 1:300,000 depending on the population studied. More than 100 LIPA gene mutations have been identified so far, 23 the most common of which is E8SJM. Individuals who are homozygous for E8SJM, which accounts for more than half of all patients with LAL-D, typically have slowly progressive disease that is diagnosed in early to mid-childhood.
The LAL protein plays a critical role in cholesterol metabolism. In healthy individuals, LDL-C is internalized via LDL receptors and brought into intracellular lysosomes for degradation. In patients with an LAL-enzyme defect, there is reduced or absent hydrolysis of cholesteryl esters and triglycerides, resulting in sequestration of free cholesterol and fatty acids within lysosomes of Kupffer cells and hepatocytes. 24, 25 The absence of free cytoplasmic cholesterol, in turn, leads to reduced feedback inhibition of hydroxymethylglutaryl-coenzyme A reductase in hepatocytes, a rate-controlling enzyme in the cholesterol synthesis pathway. 25 As a result, HDL-C synthesis is decreased, surface LDL receptors are upregulated, and very-low-density lipoprotein (VLDL) synthesis is increased. [26] [27] [28] Together, these metabolic alterations lead to the characteristic cholesterol findings of LAL-D: increased serum LDL-C and low HDL-C levels.
Clinically, these cholesterol changes are believed to be responsible for early-onset cardiovascular disease in patients with LAL-D. In the liver, progressive lipid deposition leads to fibrosis, micronodular cirrhosis, and liver failure, although the timing of these occurrences is variable. 20, 29 In the intestinal microvilli, lipid accumulation can lead to diarrhea and malabsorption, with resultant failure to thrive. 29 Therefore, LAL deficiency should be suspected in individuals with characteristic clinical findings of hepatomegaly, elevated ALT levels, elevated LDL-C levels, low HDL-C levels, or microvesicular/mixed steatosis on histology. Experimentally, staining for cathepsin D, Lysosomeassociated membrane protein 2 (LAMP-2), and lysosomal integral membrane protein 2 (LIMP-2) have been used to highlight hepatocytic lysosomes, 21 22 This paradigm must shift, given the severity of LAL-D and the availability of efficacious therapy in the form of a recombinant enzyme (sebelipase alpha) that reaches the lysosomes, corrects the metabolic defects, and reduces pathological accumulation of cholesterol esters in affected tissues in patients with LAL-D.
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Conclusion
LAL-D is a rare but progressive metabolic disease caused by reduced lysosomal acid lipase enzyme activity levels. Cholesterol esters and triglycerides eventually accumulate within intracellular lysosomes, resulting in the characteristic biochemical findings of elevated serum ALT, LDL-C, and low HDL-C levels. Clinically, patients may present with neonatal liver failure or can be asymptomatic and develop progressive liver disease later in life, depending on the degree of enzyme deficiency. Either way, LAL-D can be difficult to recognize clinically, and surgical pathologists can be instrumental in diagnosing cases if any of the classic histopathologic findings-microvesicular steatosis, mixed steatosis, or clusters of foamy histiocytes in the lobules and/or portal areas-are present. LM
